GSK has committed $270 million to gain access to early-stage assets in the cancer therapy class of antibody drug conjugates. After divesting its oncology business in 2015, the company has decided to re-enter the field, focusing on therapeutic modalities like immuno-oncology, synthetic lethality, and tumor cell targeting. They are prioritizing hematological malignancies, gynecological cancers, lung cancer, and other solid tumors, aiming to provide significant therapeutic advantages. GSK’s cancer strategy includes a mix of internally developed assets and technologies from outside the company. They recently reported new Phase 3 data showing their multiple myeloma drug outperformed a competitor, and their focus on external innovation includes partnerships and acquisitions.
Source link
At JPM, Top GSK Cancer Executive Talks Drug Targets and Oncology Strategy
